Estriol, or E3, is an estrogen that rises dramatically during pregnancy because its production depends on cooperation between the fetus and placenta. A blood test usually measures unconjugated estriol, written as uE3, as one part of second-trimester prenatal serum screening. The result is not a stand-alone diagnosis of a fetal chromosome condition or placental problem. Laboratories combine it with gestational age, maternal details, and other markers such as alpha-fetoprotein, human chorionic gonadotropin, and inhibin A to calculate a pregnancy-specific risk estimate. Low uE3 may appear with incorrect pregnancy dating, certain chromosome conditions, rare fetal steroid disorders, or an affected pregnancy, but many low results do not identify a serious problem. High values are usually less clinically specific. Outside pregnancy, estriol levels are naturally very low and testing rarely adds useful information. Correct interpretation therefore depends on why the test was ordered, the week of pregnancy, the full screening pattern, ultrasound findings, and any follow-up testing.
- Estriol in pregnancy reflects the fetoplacental unit: the fetus supplies steroid precursors that the placenta converts into E3.
- uE3 is usually a screening marker, not a diagnostic test: it is interpreted with other blood markers and maternal information.
- A low result does not prove a chromosome condition or placental failure: dating errors and other explanations are common.
- No fasting is usually required: accurate gestational age and complete pregnancy details matter more than meal timing.
- Very low or unexpected uE3 needs clinician review: follow-up may include repeat calculations, ultrasound, genetic counseling, or diagnostic testing.
Table of Contents
- What an Estriol Test Measures
- Why Estriol Is Tested During Pregnancy
- How the Test Is Done and Prepared For
- Estriol Results, MoM Values, and Ranges
- Causes of Low Estriol Results
- What High Estriol Results Can Mean
- Follow-Up After an Abnormal Result
What an Estriol Test Measures
An estriol test measures E3, one of the major naturally occurring estrogens. Estradiol is the dominant estrogen through much of the reproductive years, and estrone becomes relatively more prominent after menopause. Estriol is different because blood levels remain very low outside pregnancy and rise greatly once a pregnancy develops.
The result most often used in prenatal screening is unconjugated estriol, abbreviated uE3. “Unconjugated” means the hormone has not yet been attached to sulfate or glucuronide groups that help the body process and excrete it. Laboratories can measure estriol in serum, plasma, or urine, but current prenatal screening programs generally use maternal serum uE3.
How the fetus and placenta make estriol
Estriol production depends on a pathway sometimes called the fetoplacental unit. The placenta cannot make all of the needed steroid building blocks by itself. Instead:
- The fetal adrenal glands produce large amounts of dehydroepiandrosterone sulfate, or DHEA-S.
- The fetal liver converts much of that material into 16-alpha-hydroxy-DHEA-S.
- The placenta removes the sulfate group and uses aromatase and other enzymes to convert the precursor into estriol.
- Estriol enters the maternal circulation, where most of it is rapidly conjugated and later excreted.
Because fetal adrenal activity, fetal liver metabolism, placental enzymes, and maternal clearance all influence the final value, uE3 is not a direct measurement of any single organ. It is better understood as one biochemical signal from a linked maternal-fetal-placental system.
Estriol rises as pregnancy advances. A raw concentration that is expected at 20 weeks could be unusual at 16 weeks, so a result without accurate gestational dating has little value. This is why prenatal laboratories convert the measured concentration into a gestational-age-adjusted value rather than applying one universal normal range.
Outside pregnancy, an E3 test is rarely the best way to assess estrogen status, menopause, fertility, or ovarian function. An estradiol test generally provides more relevant information in those settings. Saliva, urine, or blood “estrogen balance” packages that emphasize estriol in a nonpregnant person may use different methods and reference intervals, and their clinical meaning can be limited.
Why Estriol Is Tested During Pregnancy
Estriol is most commonly tested as one component of a second-trimester maternal serum screen. The classic triple screen includes alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), and uE3. The quad screen adds inhibin A. Programs vary by country, laboratory, pregnancy history, and whether first-trimester screening or cell-free DNA testing has already been performed.
A quad screen usually estimates the chance of conditions such as trisomy 21, also called Down syndrome, and trisomy 18. AFP also helps screen for open neural tube defects. uE3 contributes to the mathematical pattern, but it should never be read alone as “positive” or “negative” for one of these conditions.
Typical marker patterns can include:
- Trisomy 21: uE3 and AFP may be lower than expected, while hCG and inhibin A may be higher.
- Trisomy 18: uE3, AFP, and hCG may all be lower than expected.
- Open neural tube defects: AFP may be high, while uE3 is not the primary marker.
These are population-level patterns, not diagnostic rules. A pregnancy without a chromosome condition can produce the same pattern, and an affected pregnancy may not show the expected combination.
Screening and diagnosis are different
Prenatal serum screening calculates probability. A result might report a risk such as 1 in 100 or 1 in 5,000 after considering the blood markers and maternal factors. It does not examine fetal chromosomes directly. A “screen positive” result means the calculated risk crossed the program’s cutoff, not that the fetus definitely has the condition.
Cell-free DNA screening, also called noninvasive prenatal testing, has higher screening performance for common trisomies than traditional serum screening, but it is still a screening test. Chorionic villus sampling and amniocentesis are diagnostic procedures because they obtain fetal or placental cells for chromosome or genetic analysis.
uE3 can also draw attention to uncommon disorders of steroid production or metabolism. Extremely low or undetectable values may prompt consideration of steroid sulfatase deficiency, Smith-Lemli-Opitz syndrome, fetal demise, severe placental dysfunction, or another rare cause. The full context determines whether this possibility deserves targeted investigation.
Historically, clinicians used serial estriol measurements late in pregnancy as a general measure of placental or fetal well-being. Modern ultrasound, fetal growth assessment, Doppler studies, biophysical profiles, and fetal heart-rate monitoring provide more useful information. A single estriol value is not a reliable stand-alone “placenta function test,” and routine serial E3 testing for fetal surveillance is uncommon.
How the Test Is Done and Prepared For
The test requires a routine blood draw from a vein in the arm. The blood is sent to a laboratory that measures uE3 and, when ordered as a prenatal panel, the other serum markers. Collection itself takes only a few minutes. Mild bruising, soreness, lightheadedness, or a small hematoma can occur, as with any venipuncture.
Fasting is generally unnecessary. Normal food and fluid intake do not create the major interpretation issue. Accurate pregnancy data are much more important.
Before testing, the ordering team and laboratory may need:
- the first day of the last menstrual period;
- an ultrasound-based estimated due date;
- maternal age, weight, and sometimes race or ethnicity, depending on the validated algorithm;
- whether the pregnancy is singleton or multiple;
- whether conception used in vitro fertilization or a donor egg;
- smoking status;
- insulin-treated diabetes or other specified medical details;
- the exact date and time of blood collection;
- prior prenatal screening results.
These factors can change expected marker concentrations or the calculated risk. For example, a twin pregnancy produces different marker levels from a singleton pregnancy. A dating difference of even several days can alter the expected median enough to change the multiple-of-the-median calculation.
When the sample is collected
Second-trimester serum screening is generally performed during a defined window, often about 15 through 22 weeks, with some programs preferring a narrower period for best performance. The exact accepted dates depend on the laboratory and regional screening program. A sample collected too early or too late may not be interpretable under that program’s algorithm.
If an early ultrasound gives more reliable dating than the last menstrual period, the ultrasound date is usually used. When a revised gestational age changes the risk estimate, the laboratory may recalculate the report rather than repeat the blood draw. Clinicians should avoid manually comparing raw uE3 numbers from different laboratories because assays, units, medians, and adjustment formulas differ.
Medications and medical conditions should be reported, but patients should not stop prescribed treatment to prepare for uE3 testing unless their clinician specifically directs it. Rarely, exposure to certain steroid medicines or disorders that alter steroid metabolism can affect the biochemical picture. The laboratory report and prenatal team can determine whether a drug is relevant.
A person choosing among prenatal screening options benefits from discussing timing before the blood draw. Serum screening, cell-free DNA screening, ultrasound, carrier screening, and diagnostic testing answer different questions. Ordering overlapping tests without a plan can create confusing or discordant results.
Estriol Results, MoM Values, and Ranges
There is no single normal uE3 concentration for every pregnancy. The level changes rapidly with gestational age and varies by assay. Reports may show a raw concentration in nanograms per milliliter, nanomoles per liter, or another unit, but prenatal risk calculations usually rely on the multiple of the median, or MoM.
An MoM compares the patient’s result with the median expected for a pregnancy at the same gestational age after the laboratory applies its validated adjustments.
- 1.0 MoM means the result equals the expected median.
- 0.5 MoM means it is half the expected median.
- 2.0 MoM means it is twice the expected median.
MoM values are not percentages, and 1.0 is not a target that every healthy pregnancy must meet. Normal pregnancies produce a distribution above and below the median. Screening software combines the uE3 MoM with the other analyte MoMs and maternal information to produce a condition-specific risk.
Why laboratory cutoffs differ
A report may flag uE3 below a laboratory-specific threshold, sometimes around 0.5 MoM, but the meaning of that flag depends on the complete screen. “Very low” may be defined more strictly in studies or specialty protocols, such as below 0.3 MoM or near the assay’s detection limit. These numbers should not be transferred from one program to another without checking its definitions.
Several issues can shift the result or its interpretation:
| Factor | How it can affect interpretation |
|---|---|
| Gestational age | Expected uE3 rises with advancing pregnancy, so incorrect dating can falsely lower or raise the MoM. |
| Multiple pregnancy | Marker distributions differ, and some risk calculations are less precise. |
| Maternal weight | Greater blood volume can dilute serum markers; algorithms may adjust for weight. |
| Diabetes or smoking | Some programs use correction factors because marker distributions may differ. |
| Laboratory method | Assays and population medians are not interchangeable. |
| Fetal or placental biology | Chromosome conditions, steroid disorders, growth problems, or pregnancy loss can alter uE3. |
A low uE3 flag by itself is less informative than the final risk calculation. For example, a mildly low uE3 with reassuring AFP, hCG, inhibin A, dating, and ultrasound may lead to a very different recommendation from an extremely low uE3 combined with several abnormal markers.
A “negative” serum screen substantially lowers the estimated chance of the conditions included in the algorithm, but it cannot guarantee an unaffected pregnancy. It also does not screen for every genetic disorder, birth difference, or pregnancy complication. A “positive” screen means more information should be offered, not that a diagnosis has been established.
Causes of Low Estriol Results
Low uE3 has a broad differential diagnosis. The first step is to confirm that the pregnancy information and laboratory calculation are correct. The degree of reduction, the other serum markers, ultrasound findings, and clinical history then help narrow the possibilities.
Incorrect gestational age or data entry
A pregnancy dated later than it actually is can make the measured uE3 appear low for the stated week. An incorrect maternal weight, unrecorded twin pregnancy, or other input error can also affect the MoM and risk estimate. Reviewing the original requisition and ultrasound dating can resolve some abnormal reports without implying fetal disease.
Chromosome conditions
Lower-than-expected uE3 may contribute to screening patterns associated with trisomy 21 or trisomy 18. The value alone cannot identify either condition. The final risk is based on all markers and maternal age, and confirmation requires diagnostic testing if the patient chooses it.
Steroid sulfatase deficiency
Steroid sulfatase deficiency prevents the placenta from efficiently converting sulfated fetal steroid precursors into estrogens. It can cause very low uE3 while the pregnancy otherwise appears structurally normal. The condition is commonly related to an X-linked deletion and may be associated with X-linked ichthyosis in a male child, causing dry, scaly skin after birth. It may also be linked with prolonged labor or difficulty with cervical dilation because placental estrogen production is reduced.
A very low uE3 does not establish this diagnosis. Genetic counseling and targeted testing may be considered after review of fetal sex, family history, ultrasound, and the degree of reduction.
Smith-Lemli-Opitz syndrome
Smith-Lemli-Opitz syndrome is a rare inherited disorder of cholesterol synthesis. Affected fetuses may produce low steroid precursors, leading to markedly reduced uE3. Ultrasound may show growth restriction or structural differences, but findings vary. Diagnosis may involve testing amniotic fluid for sterol metabolites or performing molecular genetic testing when clinically appropriate.
Fetal compromise, pregnancy loss, or severe placental disease
Because estriol production depends on living fetal tissues and an active placenta, a sharp or extreme reduction can occur with fetal demise or severe compromise. Symptoms such as bleeding, fluid leakage, severe abdominal pain, or reduced fetal movement later in pregnancy require prompt assessment rather than waiting for a screening report.
Low serum markers have also been associated in studies with outcomes such as fetal growth restriction, preterm birth, or other placenta-mediated complications. Association does not make uE3 a reliable stand-alone prediction tool. Current guidance does not support ordering an isolated serum marker solely to forecast placental complications, and a mildly abnormal value does not automatically justify medication or intensive surveillance.
Other uncommon explanations
Rare fetal adrenal, liver, aromatase, or steroid metabolism disorders can reduce estriol synthesis. Maternal treatment with certain corticosteroids may alter precursor production in selected circumstances. Severe illness and assay interference are less common considerations. These possibilities require specialist interpretation; they are not conclusions a patient should draw from an online reference range.
The most concerning pattern is usually an extremely low or undetectable uE3 that remains unexplained after dating and data review, especially when another marker, ultrasound, or clinical finding is abnormal. A mild isolated decrease is much more common and often has a reassuring outcome.
What High Estriol Results Can Mean
A high uE3 result is generally less specific than a low result. Estriol normally rises throughout pregnancy, so an apparently high concentration may reflect a pregnancy that is farther along than recorded. Multiple gestation can also increase total hormone production and requires a different reference model.
Other explanations include normal biological variation, differences in maternal weight or metabolism, and assay-related variation. Some pregnancies simply fall above the median without a disease process. The prenatal screen’s final risk calculation, not the isolated upward flag, should guide interpretation.
High uE3 is not a standard diagnostic marker for “estrogen dominance,” an unusually strong placenta, a large fetus, or a particular maternal symptom. It should not be treated with supplements, hormone blockers, or diet changes. Estriol values are part of a screening calculation, not a hormone level that patients need to optimize.
When several serum markers are abnormal, the pattern may change the calculated aneuploidy risk or raise concern about pregnancy outcomes. The clinician may verify dating and review ultrasound growth and anatomy. Even then, the results remain probabilistic.
Outside pregnancy, a detectable or higher-than-expected estriol result can reflect laboratory method, estrogen medication, compounded hormone products, pregnancy, or conversion of other estrogens in the liver. Nonpregnant E3 reference intervals are often low and method-specific. Estriol is not usually the first test used to investigate menstrual changes, infertility, menopause symptoms, or an estrogen-producing tumor. A broader female hormone evaluation chosen for the actual symptom is more informative than isolated E3 testing.
Urine hormone panels may report estriol metabolites and ratios, but those results are not interchangeable with serum uE3 used in prenatal screening. A ratio labeled “high” by a commercial wellness panel does not carry the same meaning as a pregnancy serum result and should not be used to diagnose placental function.
Follow-Up After an Abnormal Result
Follow-up should match the complete report rather than the word “low” or “high.” The prenatal clinician usually begins by confirming the basics: gestational age, number of fetuses, maternal data, sample timing, laboratory method, and the other analyte values.
A practical evaluation may include:
- Review or repeat ultrasound dating. A reliable first-trimester ultrasound often provides the best estimate. If the dates change enough, the laboratory may recalculate the MoMs and risk.
- Examine the full screening pattern. AFP, hCG, inhibin A, and uE3 must be considered together. The report’s calculated risks are more useful than one raw result.
- Offer genetic counseling. A counselor or maternal-fetal medicine specialist can explain the condition-specific probability, testing options, limitations, and the possible meaning of extremely low uE3.
- Discuss additional screening or diagnostic testing. Depending on timing and prior testing, options may include cell-free DNA screening, detailed ultrasound, amniocentesis, chromosome analysis, microarray, or targeted genetic and biochemical testing.
- Plan pregnancy surveillance when justified. Ultrasound assessment of anatomy and growth, Doppler studies, or later antenatal testing may be appropriate when the whole clinical picture suggests placental or fetal risk.
A normal detailed ultrasound can be reassuring, but it cannot exclude every chromosome or metabolic condition. Cell-free DNA can refine risk for selected chromosome conditions but does not diagnose steroid sulfatase deficiency or Smith-Lemli-Opitz syndrome. Amniocentesis provides diagnostic material but is invasive and carries a small procedure-related risk. The choice depends on the patient’s values, gestational age, specific risk estimate, and how much certainty is desired.
Patients should contact their maternity team promptly for heavy bleeding, severe or persistent abdominal pain, fluid leakage, fever, severe headache with vision changes, or reduced fetal movement after movement has become established. Those symptoms need clinical assessment regardless of the estriol result.
For a mildly abnormal isolated uE3 with correct dating, reassuring other markers, and a normal ultrasound, clinicians may recommend routine care or limited additional monitoring. For an undetectable result, a strongly positive combined screen, abnormal anatomy, or concerning symptoms, specialist review is more urgent. No estriol result should be used alone to start aspirin, change hormone treatment, predict delivery timing, or conclude that the placenta is failing.
References
- Prenatal Genetic Screening 2025 (Review)
- Technical Update No. 462: Abnormal maternal serum markers and adverse pregnancy outcomes 2025 (Guideline)
- Biochemical Screening for Fetal Trisomy 21 2023 (Review)
- How to Manage Low Estriol Levels in Pregnancies, One Center Experience 2022 (Review)
- Metabolism of endogenous and exogenous estrogens in women 2024 (Review)
Disclaimer
This information is educational and does not replace prenatal care, genetic counseling, or interpretation by the laboratory and maternity team. Estriol results must be assessed with gestational age, the complete screening panel, ultrasound findings, and personal history. Seek urgent maternity assessment for concerning pregnancy symptoms even when a screening result is reassuring.
